source
- FDA Approves Zenocutuzumab for NRG1 Fusion+ Cholangiocarcinomaonclive · 3mo ago↗ source
- STAT+: Capricor Therapeutics accuses Nippon Shinyaku of slow-walking plans on Duchenne drugCapricor Therapeutics has accused Nippon Shinyaku and its U.S. subsidiary of botching the rollout of a Duchenne muscular dystrophy treatment.STAT · 3mo ago↗ source
- Trump plans to fire Makary from FDA role, according to reportsFDA Commissioner Marty Makary is expected to be fired from his role, according to multiple media reports. The plans haven’t been finalized and could still change, said the Wall Street Journal ...Endpoints · 3mo ago↗ source